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Despite the protection provided by several factors, including maternal antibodies, the burden of malaria in young
infants may be higher than previously thought. Infants with congenital or neonatal malaria may have a different
clinical presentation than older children, and diagnosis may be confused with other neonatal diseases due to an
overlap of clinical manifestations. In addition, there is little information on the use of artemisinin-based combination
therapy in young infants. There is the need for a more accurate estimate of the parasite prevalence and the
incidence of clinical malaria in infants under 6 months old, as well as a better characterization of risk factors,
pharmacokinetic profiles, safety and efficacy of currently available anti-malarial treatments, in order to develop
evidence-based treatment guidelines for this population.
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Although the burden of Plasmodium falciparum malaria
in children aged under five years is well documented [1],
there is limited and contradictory information about the
impact of the disease in infants under six months of age.
Early studies concluded that malaria was uncommon in
young infants and that clinical disease was of little im-
portance [2-4], despite several early reports of a uniform
rise in parasite prevalence during the first few months of
life [5]. Young infants with malaria may have different
clinical manifestations [6,7] and lower parasite densities
[5] than older children. Nevertheless, even low-density
infections (1–500 parasites/μL) in infants can result in
anaemia if left untreated [8], and may rapidly progress to
become life-threatening [9].
Neonatal malaria is considered a rare occurrence due
to the protective effect of maternal immunity after birth.
Maternal immunoglobulin G (IgG) antibodies are
acquired by the fetus via the placenta in utero [10], al-
though there is only limited evidence suggesting a pro-
tective role of these passively acquired antibodies against* Correspondence: udalessandro@mrc.gm
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distribution, and reproduction in any mediummalaria parasites [11]. IgG levels are thought to decrease
variably during the first year of life [12]. Neonates may
also be protected through factors that inhibit parasite
growth, such as lactoferrin (which binds iron) and
secretory IgA, found in breast milk and in maternal and
infant sera [13]. Parasite replication depends on the
metabolic substrate para-aminobenzoic acid (pABA),
which is present only in low levels in breast milk [10].
Haemoglobin F (HbF), present in high concentrations at
birth [10], can inhibit parasite development [14] and can
protect the infant in the first few months of life. The
parasite antigen P. falciparum erythrocyte membrane
protein-1 (PfEMP-1) mediates cytoadherence of infected
red blood cells to the endothelial cells lining the blood
vessels. HbF and maternal IgG act cooperatively to im-
pair the cytoadherence of parasitized erythrocytes in the
first few months of life by altering PfEMP-1 display on
HbF RBCs, and by binding PfEMP-1 and preventing se-
questration of parasitized RBCs, respectively [15]. HbF
levels decline after a peak at 6 weeks of age [10], and as
both HbF and IgG disappear from circulation, infant
susceptibility to P. falciparum malaria increases [15].
Iron-deficiency anaemia is common in sub-Saharan
Africa and can cause impaired cognitive and motor devel-
opment, growth impairment and anorexia. Consequently,entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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children below two years of age. However, iron status has
been shown to have an effect on the risk of malaria in
young infants, with iron deficiency potentially causing a
decrease in malaria morbidity and mortality [16].
In Mozambique and Benin, placental malaria has been
associated with shorter time to first episode of infant
malaria [17,18]. The mechanisms underlying this associ-
ation are unclear but may relate to prenatal foetal prim-
ing [19]. Therefore, some reduction of malaria risk in
infants can probably be achieved by improving malaria
control in late pregnancy.
Burden of malaria in infants aged less than six
months
Malaria in infants is classified according to the time of
infection. Congenital malaria, defined as asexual para-
sites detected in the cord blood or in the peripheral
blood during the first week of life [20], is due to trans-
mission from the mother through the placenta just be-
fore or during delivery [21], while neonatal malaria,
which can occur within the first 28 days of life, is due to
an infective mosquito bite after birth [21]. Differentiating
between congenital and acquired neonatal malaria can
be difficult, especially in areas of intense malaria trans-
mission [22]. Various studies across Africa have demon-
strated that 7–10% of newborns may have malaria
parasites in their cord blood [8], in some cases either
without evidence of an active maternal infection or with
parasite genotypes different to those found in the
mother. This suggests transplacental passage of parasites
followed by clearance from maternal and placental
blood, with persistence in the foetus [8,23,24].
Recent reports suggest that malaria in infants under
six months of age may not be uncommon, although data
on prevalence and outcome are still contradictory [25].
Prevalence of infection can vary between 0% and 27%
[9,25-33], while the percentage of deaths attributed to
malaria (as determined by verbal autopsy) may be be-
tween 20.1% and 46.2% [34]. The occurrence of infection
in utero is also reflected by the prevalence of splenomeg-
aly at one month of age, which can be as high as 80%,
indicating an early development of a splenic response to
the infection [5,35].
In Mozambique, clinical malaria incidence in infants
aged 1– < 6 months was substantial (320/1,000 child-
years at risk in 2003–2004 and 146/1,000 child-years at
risk in 2004–2005) [36]. Reports of congenital malaria
have predominantly come from Nigeria; the prevalence
of parasitaemia in infants in these studies as well as in
those from other malaria-endemic regions varied widely –
between 0.7% and 46.7% [20,33,37-51]. Parasite dens-
ities in neonatal blood were also varied, although most
infections were of low density [20,40,42,48-50,52,53].However, differences in transmission dynamics, small
sample sizes and lack of details on quality control and
sample selection procedures make the interpretation of
these findings difficult [20,25].
Malaria infections (mean geometric parasite density =
533 parasites/μl of blood, as detected by PCR) were
common in Ghanaian infants less than 6 months of age
(13.6% in newborns; 1.5–9.7% in those aged from 2–
26 weeks), although clinical malaria symptoms were rare
or uncommon (fever, vomiting, diarrhoea and coughing
occurred in 1.8%, 1.8%, 3.0% and 4.8% of infants aged 0–
3 months, respectively, and in 4.5%, 3.0%, 8.0% and
10.6% of infants aged 3–6 months) [54]. In Mozambique,
although malaria in infants aged under six months
represented less than 20% of the total outpatient visits,
infants with malaria were admitted in a significantly
higher proportion than children aged 1–4 years [36].
The impact of malaria in this age group is also illu-
strated by a greater difference in mean haematocrit be-
tween malaria and non-malaria cases in infants aged
from 2–12 months (4.9%) than in children aged 5 years
or above (1.8%). Among infants aged under six months
attending an urban hospital in Nigeria, 27.1% had a posi-
tive blood slide and a significantly lower haematocrit
(33.0%) compared with those who were uninfected
(35.1%)(p = 0.003). Indeed, a haematocrit of less than
33% was the most common clinical finding among
infected infants, while the occurrence of fever was 4%
[9].
A systematic review of age-patterns of malaria revealed
that as transmission increased, there was a shift of clin-
ical malaria towards younger age groups, regardless of
seasonality [55]. As transmission intensity increased and
seasonality decreased, severe cases became more fre-
quent in the younger ages. Nevertheless, wherever a
comparison between age groups was possible, malaria
mortality was higher in younger children, with the peak
age shifting towards infants as transmission became
more intense [55].
Clinical signs and symptoms and malaria
diagnosis in infants aged under six months
Signs and symptoms of congenital malaria include fever,
anaemia, splenomegaly, hepatomegaly, jaundice, vomit-
ing, diarrhoea, poor feeding, restlessness, drowsiness,
pallor, respiratory distress, cyanosis, and possibly convul-
sions [39,56].
Malaria in young infants may be asymptomatic [6,7],
or it may be difficult to diagnose because the clinical
presentation may mimic other diseases, such as sepsis
[33]. Indeed, congenital malaria may be more common
in newborns with suspected or confirmed sepsis (28.6%)
[38,47]. It is unclear what influence infant HIV infection
has on these risks.
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nose malaria in young infants may be limited [57,58],
and any issues with quality or accuracy of the diagnostic
technique may result in the diagnosis of malaria being
missed [59]. In many malaria-endemic countries, infants
and children frequently die at home [60] and the cause
of death remains undetermined and unrecorded
[17,34,61]. Therefore, the overall malaria mortality in
infants aged under six months is highly uncertain. As
approximately 40% of all child deaths occur in the neo-
natal period, and many deliveries occur outside health
facilities, the proportion of these deaths that is malaria-
related is unclear [60].
Pharmacokinetics of anti-malarials in young
infants
Due to the dynamic developmental changes experienced
by infants aged under 6 months, the pharmacokinetic
profiles of anti-malarials may be different than in older
children, and age-dependent dose adjustments may be
necessary [62]. For example, gastric emptying is slower
in neonates and young infants, and is only comparable
with adults after six months of age. Absorption of drugs
is also affected by intestinal motor activity and villous
formation, both of which mature by week 20 [62]. Drug
metabolism may be altered as enzyme systems, such as
the hepatic enzymes, are immature (anti-malarials are
typically metabolized in the liver) [63], possibly resulting
in an enhancement of bioavailability [62]. Activity of
such metabolizing enzymes is typically low at birth and
rapidly develops over the first 1–2 years of life [64].
Current national recommendations for treating
infants aged under 6 months
As the burden of disease in infants under 6 months of
age is not well defined, this age group has been excluded
from previous clinical trials and national treatment
guidelines on uncomplicated P. falciparum malaria.
Thus, oral anti-malarials recommended as first- and
second-line therapies are frequently used off-label, based
on the recommended mg/kg dosing schedule for older
children [28].
Issues with currently available anti-malarials
There is little information on the use of artemisinin-
based combination therapy (ACT) in young infants, to
the extent that many of them carry label restrictions for
this age group [63]. Accurate dosing is particularly im-
portant, but this is difficult when paediatric formulations
are unavailable. Nevertheless, young infants with malaria
should receive appropriate treatment. Among the
recommended ACT, excluding the combination contain-
ing sulphadoxine-pyrimethamine that is not recom-
mended during the first 6 weeks of life [65], there is noevidence of specific serious toxicity [63]. However, add-
itional efforts should be made to establish their safety
profile, the correct dosage and formulation, so that
young infants with malaria can be managed adequately.
With these issues in mind, it must be considered how
ACT could be used to treat malaria in infants aged
under six months. There are no official data on how to
use ACT in this age group, despite the fact that malaria
can occur at a very young age and that ACT offers
greater efficacy and tolerability compared with quinine,
which is often used in infants with clinical malaria. Fur-
thermore, the use of a unified first-line therapy could
offer benefits for healthcare providers with similar anti-
malarial use for the whole population, as well as logis-
tical benefits in terms of procurement and distribution.
The safety profile of these combination therapies in
young infants should be established.
Preventive treatment
Previous studies have shown that chemoprophylaxis in
infants has the potential to reduce malaria-related mor-
bidity and mortality [66]. In The Gambia, infants receiv-
ing weekly chloroquine from birth until the age of two
years had fewer episodes of malaria, grew better, and
had higher haemoglobin levels than the control group
[67].
Some studies of intermittent preventive treatment
(IPT) in infants (IPTi) have timed the doses of anti-
malarial to coincide with routine vaccinations delivered
by WHO’s Expanded Programme on Immunization
(EPI) at 2, 3 and 9 months. In a pooled analysis of six
randomized, placebo-controlled trials of IPTi using
sulphadoxine-pyrimethamine delivered at the same time
as EPI immunizations, a protective efficacy against clin-
ical malaria of 30.3% was reported [68].
Seasonal malaria chemoprevention (SMC), previously
referred to as IPT in children (IPTc), involves the admin-
istration of full anti-malarial treatment courses during
the malaria season to children aged 3–59 months [69].
The WHO recommends that SMC be used in areas of
high seasonal malaria transmission across sub-Saharan
Africa, and that treatment with amodiaquine plus
sulphadoxine-pyrimethamine should be given at monthly
intervals from the start of the transmission season, up to
a maximum of four doses [69]. The main potential risks
associated with SMC are safety and drug resistance [70].
However, SMC may provide a substantial protective effect
against malaria [70], and is a potentially valuable tool that
could contribute to reducing the malaria burden in
infants aged over three months in areas with seasonal
transmission.
The candidate malaria vaccine RTS,S/AS01 adminis-
tered to infants aged 6–12 weeks at the time of the first
vaccination provided modest protection against both
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on whether this vaccine could be included in the routine
panel of infants’ immunization [72]. However, additional
analyses are needed to understand the reasons of the
observed lower efficacy in young infants as compared
with older infants and children (aged 5–17 months) [73].
Future clinical studies
There are several ongoing or planned clinical studies
aiming to obtain more accurate estimates of the malaria
burden and parasite prevalence in infants aged less than
6 months living under different endemic conditions, as
well as the safety and efficacy of currently available ACT
in this population. Future longitudinal studies should
also characterize infant iron status in relation to subse-
quent malaria risk, and relate findings to the occurrence
of placental malaria.
A multicentre descriptive study is underway, aiming to
assess malaria morbidity (prevalence and incidence) and
corresponding risk factors in young infants, compared
with their siblings, in areas of seasonal low (The Gambia)
and high (Guinea) malaria transmission, and in an area
with intense, perennial transmission (Benin).
A multicentre trial will evaluate the safety, pharmaco-
kinetics and efficacy of dispersible artemether-
lumefantrine tablets in infants weighing under 5 kg with
uncomplicated P. falciparum malaria. This trial, spon-
sored by Novartis and in association with MMV, com-
menced in 2012 and involves sites in Benin, Burkina
Faso, the Democratic Republic of the Congo, Nigeria
and Togo.
Another study planned at the College of Medicine at
the University of Malawi will assess the population
pharmacokinetics and the safety and efficacy of ACT in
infants weighing under 5 kg or aged less than 6 months.
Knowledge gained from such studies will assist in
guiding the development of evidence-based treatment
guidelines for this population.
Conclusions
The perception that malaria is uncommon in young
infants has resulted in the paucity of information cur-
rently available and the lack of evidence-based treatment
guidelines in this population. Many children are dying
before malaria is diagnosed. In resource-constrained set-
tings, diagnostic techniques may not be available, or
malaria may not be recognized due to overlapping symp-
toms with other neonatal illnesses such as sepsis [33].
Malaria in infants aged under six months is not a rare
occurrence in endemic areas and its burden may be
underestimated. Therefore, it is necessary to collect reli-
able data on the malaria burden in this population.
Awareness by health professionals should increase so
that any infant aged under 6 months brought to a healthfacility in a malaria-endemic area with unexplained fever
or suspected sepsis should be systematically screened for
malaria. Current policy for malaria diagnosis dictates
that all fevers in all age groups and settings should be
tested for malaria before treatment is initiated.
ACT is being used off-label in this vulnerable patient
group, with physicians using a pragmatic approach to
guide dosing. At this time, a clear recommendation on
the use of ACT could be difficult, due to a lack of data
in infants with a body weight of less than 5 kg (less than
4.5 kg for artesunate plus amodiaquine). A more accur-
ate estimate of the disease burden and parasite preva-
lence, risk factors for infection including iron status, as
well as the pharmacokinetic profiles, safety and efficacy
of currently available ACT in early infancy from data
provided by clinical trials that are planned or underway
will contribute to the development of evidence-based
treatment guidelines for this population, as well as aid
the research and development of new drugs. It is defin-
itely worth providing malaria control strategies that are
aimed directly at this vulnerable age group, in a bid to
reduce infant mortality.
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